Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6919)
All Articles published online
|
Publishing Process of This Article
|
Mar 21, 2019 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mak LY, To WP, Wong DKH, Fung J, Liu F, Seto WK, Lai CL, Yuen MF. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol 2019; 25(11): 1398-1408 [PMID: 30918432 DOI: 10.3748/wjg.v25.i11.1398] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v25/i11/1398.htm |
| Number | Citing Articles |
| 1 |
Kantoku Nagakawa, Masaaki Hidaka, Takanobu Hara, Hajime Matsushima, Hajime Imamura, Takayuki Tanaka, Tomohiko Adachi, Akihiko Soyama, Kengo Kanetaka, Susumu Eguchi, Jincheng Wang. Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein is unsuitable as a diagnostic marker of occult hepatocellular carcinoma in end-stage liver cirrhosis. PLOS ONE 2023; 18(11): e0293593 doi: 10.1371/journal.pone.0293593
|
| 2 |
Tai-Chung Tseng, Cheng-Yuan Peng, Yao-Chun Hsu, Tung-Hung Su, Chia-Chi Wang, Chun-Jen Liu, Hung-Chih Yang, Wan-Ting Yang, Chia-Hsin Lin, Ming-Lung Yu, Hsueh-Chou Lai, Yasuhito Tanaka, Mindie H. Nguyen, Chen-Hua Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. Liver Cancer 2020; 9(2): 207 doi: 10.1159/000504650
|
| 3 |
Alessia Virzì, Victor Gonzalez-Motos, Simona Tripon, Thomas F. Baumert, Joachim Lupberger. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. Journal of Clinical Medicine 2021; 10(5): 977 doi: 10.3390/jcm10050977
|
| 4 |
Lung-Yi Mak, Danny Ka-Ho Wong, Ka-Shing Cheung, Rex Wan-Hin Hui, Fen Liu, James Fung, Wai-Kay Seto, Man-Fung Yuen. Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection. Digestive Diseases and Sciences 2022; 67(11): 5127 doi: 10.1007/s10620-022-07429-4
|
| 5 |
Chih-Lin Lin, Jia-Horng Kao. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clinical and Molecular Hepatology 2023; 29(3): 605 doi: 10.3350/cmh.2022.0342
|
| 6 |
James Lok, Kosh Agarwal. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021; 13(7): 1333 doi: 10.3390/v13071333
|
| 7 |
Ian Baudi, Takako Inoue, Yasuhito Tanaka. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. International Journal of Molecular Sciences 2020; 21(3): 949 doi: 10.3390/ijms21030949
|
| 8 |
Shu Feng, Zhonghao Wang, Yanhua Zhao, Chuanmin Tao. Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-67471-y
|
| 9 |
Takako Inoue, Yasuhito Tanaka. Novel biomarkers for the management of chronic hepatitis B. Clinical and Molecular Hepatology 2020; 26(3): 261 doi: 10.3350/cmh.2020.0032
|
| 10 |
Takako Inoue, Yasuhito Tanaka. Comprehensive Guide to Hepatitis Advances. 2023; : 31 doi: 10.1016/B978-0-323-98368-6.00009-4
|